IRMD - IRadimed Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

IRMD

IRADIMED CORPORATION

NASDAQ

$87.45

▲ UP 1.83% (1.57)

KEY STATISTICS

Market Cap$1.10 B

52w High$107.90

52w Low$71.34

Dividend Yield1.40%

FrequencyQuarterly

P/E43.94

Volume68.87K

Shares Out.12.78M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Roger E. Susi

COMPENSATION 2026

Salary$385,598

Stock Awards$0

Incentive Plan Pay$395,000

All Other Comp.$0

Total$780,598

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 16, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

166

PRICE TARGET

Target High$120.00

Target Low$60.00

Target Median$120.00

Target Consensus$100.00

UPCOMING EARNINGS

DateNov 2, 2026

DayMonday

Rev. Est.$23.43M

NOV

MON

ETFS HOLDING THIS STOCK

ETFS HOLDING

133

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

37.63%

HOLDERS

293

TOP 8 OF 293 · RANKED BY POSITION SIZE

Nine Ten Capital Management LLC

Renaissance Technologies LLC

488.8K sh

$34.78M

Copeland Capital Management, LLC

433.5K sh

$30.85M

Kayne Anderson Rudnick Investment Management LLC

397.0K sh

$37.94M

T. Rowe Price Investment Management, Inc.

318.7K sh

$30.45M

PRICE

$87.45 ▲ UP 1.83% (+$1.57)

About IRadimed Corporation

https://www.iradimed.com ↗

Iradimed Corporation develops and markets MRI-compatible medical devices, including infusion pumps, vital signs monitors, and accessories, serving healthcare facilities worldwide through direct sales and distributors.

INDUSTRY

Medical - Devices

A PRODUCT IRADIMED CORPORATION IS KNOWN FOR

MRidium® 3870 MRI IV Infusion Pump System

IRadimed's FDA-cleared, non-magnetic MRI-compatible infusion pump ensures safe, accurate fluid delivery within MRI environments, representing their next-generation, market-leading solution and key strategic focus.

COMPETITORS

COMPETITOR

IRadimed in 2025

SENTIMENT: + POSITIVE

EARNINGS · NOVEMBER 2025

IRadimed Reports Record Third Quarter 2025 Financial Results, Leading to All-Time High Stock Price and Special Dividend

IRadimed Corporation announced record revenue of $21.2 million for the third quarter of 2025, a 16% increase year-over-year, and raised its full-year guidance. This strong performance was a key catalyst in the company's stock reaching an all-time high in December 2025 and the subsequent announcement of a special cash dividend of $0.50 per share.

CAPITAL ALLOCATION · DECEMBER 2025 · ANNOUNCED

IRadimed Announces $0.50 Per Share Special Cash Dividend Amidst Record Financial Performance

IRadimed Corporation's Board of Directors approved a special cash dividend of $0.50 per share, signaling a significant move to return capital to shareholders. This decision follows 17 consecutive quarters of record revenue and reflects the company's strong cash position and positive outlook.